Xeljanz® is the commercial brand name of Tofacitinib Citrate Tablets, an orally active Janus kinase (JAK) inhibitor developed by Pfizer. It selectively inhibits JAK family enzymes to block multiple pro-inflammatory cytokine signaling pathways, suppressing excessive immune and inflammatory responses.
Main Indications
Treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response or intolerance to methotrexate;
Treatment of adult patients with active psoriatic arthritis;
Treatment of adult patients with moderately to severely active ulcerative colitis.
Clinical Research
Global multicenter phase III clinical trials verified that oral tofacitinib achieves significant improvement in joint symptoms, physical function and inflammatory indicators in patients with rheumatoid arthritis;
Long-term extension trials demonstrated sustained therapeutic benefits and a recognizable safety profile during continuous administration;
Registered clinical studies conducted in Chinese patient populations confirmed consistent efficacy and tolerability compared with global trial cohorts.
Common Side Effects
Severe but important risks: Serious infections, thromboembolic events, elevated risk of malignancy, abnormal liver function, elevated lipid levels;
Common mild adverse reactions: Upper respiratory tract infection, headache, diarrhea, nasopharyngitis, hypertension and nausea.
Approval Status in China
Original drug Xeljanz® (Tofacitinib Citrate Tablets) was officially approved for marketing in China in 2017, with the specification of 5mg per tablet, 28 tablets per bottle. It is currently a prescription drug included in China’s Category B medical insurance catalogue.
Buy Xeljanz (Tofacitinib Citrate Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
